Finally, Signature 3 is associated with inactivating mutations in BRCA1 and BRCA2 genes, indicating that abrogation of functional HR- and/or NHEJ-mediated repair contributes considerably to breast cancer development, even in patients not harbouring a germline mutation in either of these two genes. The gene discussed is BRCA2; the disease is breast carcinoma.